TET2 and B-cell non-Hodgkin lymphoma: Somatic alteration of TET2, TET1/TET2 deficiency (TET1/2 double knockout), and TET2/TET3 disruption (TET2/3 double knockout) can lead to a wide range of myeloid and lymphoid malignancies, late-onset B-cell lymphoma, and rapid and fully penetrant myeloid leukemia[124].